Teprotumumab for the Treatment of Active Thyroid Eye Disease

Original Article

R.S. Douglas, G.J. Kahaly, A. Patel, S. Sile, E.H. Thompson, R. Perdok, J.C. Fleming, B.T. Fowler, C. Marcocci, M. Marinò, A. Antonelli, R. Dailey, G.J. Harris, A. Eckstein, J. Schiffman, R. Tang, C. Nelson, M. Salvi, S. Wester, J.W. Sherman, T. Vescio, R.J. Holt, and T.J. Smith

N Engl J Med 2020;382:341-352

Course summary
Available credit: 
  • 1.00 AMA PRA Category 1 Credit
  • 1.00 Participation
Course opens: 
01/22/2020
Course expires: 
01/23/2022

Available Credit

  • 1.00 AMA PRA Category 1 Credit
  • 1.00 Participation

Course closed

This course closed on Sunday, January 23, 2022 - 11:59pm.